Keros Therapeutics CFO Resigns; Interim CFO Annita Tanini Named

What Happened Keros Therapeutics (KROS) filed an 8-K on July 22, 2026 reporting that Chief Financial Officer Keith Regnante resigned effective August 3, 2026 to pursue other opportunities. The Board appointed Annita Tanini, the company’s Corporate Controller and Vice President, Finance, as interim principal financial officer and principal accounting officer, effective August 4, 2026. The resignation was voluntary and not due to any disagreement with the company regarding accounting or financial matters. The company has begun a search for a permanent CFO.

Key Details

• Effective dates: Regnante’s resignation effective August 3, 2026; Tanini’s interim appointment effective August 4, 2026.
• Tanini’s pay package as interim CFO: $302,300 annual base salary and eligibility for an annual cash bonus with a 30% target.
• Tanini termination protections: if terminated without cause or she resigns for good reason, she would be eligible for six months’ base pay and up to six months of COBRA premium payments (subject to release conditions).
• Regnante’s separation benefits are limited to accrued base salary through the separation date, reimbursement of unpaid business expenses, and the option to elect COBRA at his own expense; no additional severance was disclosed.

Why It Matters A CFO transition is a material leadership change that investors watch because it affects financial oversight and reporting continuity. The company appointed an experienced internal finance leader as interim CFO and stated the resignation was voluntary and not due to accounting disputes, which reduces immediate regulatory or governance concerns. Investors should note the disclosed compensation terms and that the company is conducting a search for a permanent CFO.